CGM in the Hospital: Is It Ready for Prime Time?
Elizabeth O BuschurEileen FauldsKathleen DunganPublished in: Current diabetes reports (2022)
Historically, most evidence for CGM use in the inpatient setting was limited to small studies utilizing outdated CGM technology and analyzing accuracy of sensor measurements. Previous studies have shown reduced sensor accuracy during extreme hypo- or hyperglycemia, rapid fluctuations of glucose, compression of the sensor itself, and in those who are critically ill. Studies that are more recent have shown CGM to have adequate accuracy and may be effective in reducing hypoglycemia in hospitalized patients; some studies have also showed improvement in time in target glycemic range. Furthermore, CGM may reduce nursing workload, cost of inpatient care, and use of personal protective equipment and face-to-face patient care especially for patients during the COVID-19 pandemic. This review will describe the evidence for use of CGM in hospitalized critically ill or non-critically ill patients, address accuracy and safety considerations, and outline paths for future implementation.
Keyphrases
- healthcare
- case control
- palliative care
- mental health
- type diabetes
- end stage renal disease
- quality improvement
- primary care
- ejection fraction
- chronic kidney disease
- acute care
- newly diagnosed
- adipose tissue
- emergency department
- blood glucose
- skeletal muscle
- oxidative stress
- patient reported outcomes
- metabolic syndrome
- current status
- quantum dots
- chronic pain
- weight loss
- affordable care act